Religare Enterprises Limited announces a leadership change

Following the RBI approval effective 3 November 2026, Religare’s Board comprises 6 Independent Directors and 7 Non-Independent Directors—a 6:7 ratio. The four newly approved appointees—Dr. Anand Chand Burman, Aditya Chand Burman, Mohit Burman and Jimeet Vipul Modi—were specifically designated as Non-Executive, Non-Independent Directors. ^[1]

The six Independent Directors are Rajender Mohan Malla, Malay Kumar Sinha, Praveen Kumar Tripathi, Preeti Madan, Ranjan Dwivedi and Shrikant Shreeniwas Somani. The pre-existing Non-Independent Directors comprise Arjun Lamba, Suresh Mahalingam and Gurumurthy Ramanathan. ^[2]

Alignment with minimum requirements

• Companies Act, 2013: Section 149(4) requires a listed public company to have at least one-third of its Board as Independent Directors. For a 13-member Board, this translates into a practical minimum of 5 Independent Directors after rounding up.
• SEBI LODR: Where the Chairperson is a Non-Executive Director, the normal minimum is also one-third Independent Directors. Rajender Mohan Malla, an Independent Director, was continued as Non-Executive Chairperson for the quarter from 1 October to 31 December 2026. ^[3]

Accordingly, the current 6 Independent Directors exceed the five-director minimum by one, and the Board is compliant with the one-third test under both frameworks. The Board would not meet a 50% Independent Director threshold—six out of thirteen is below half—but that higher threshold would generally become relevant if the applicable SEBI LODR conditions requiring half the Board to be independent were triggered, such as the absence of a regular Non-Executive Chairperson or a qualifying relationship involving the Chairperson.

The four appointments do not enlarge the Committee of Independent Directors (CID), but they can increase the numerical quorum for a full Board meeting. All four appointees—Dr. Anand Chand Burman, Aditya Chand Burman, Mohit Burman and Jimeet Vipul Modi—are designated Non-Executive and Non-Independent Directors ^[1]. Therefore, they cannot be counted as independent directors or added to the CID merely because they join the Board.

Impact on the CID and open-offer recommendation

Regulation 26 of the SEBI SAST Regulations requires the target company’s Committee of Independent Directors to issue reasoned recommendations on the open offer ^[4]. The new Burman nominees therefore:

• do not obtain membership or voting rights on the CID;
• do not dilute the CID’s independent-director character;
• do not change the CID’s recommendation mechanism; and
• cannot convert the open-offer recommendation into a vote controlled by the full Board.

The company’s listed Board roster had six unique independent directors and three non-independent directors before these four appointments, although the precise post-appointment CID membership could not be confirmed from the cited disclosures ^[2]. Any formal CID reconstitution would require a separate company action; it does not follow automatically from these appointments.

Effect on Board quorum and voting

Assuming there were no intervening resignations or appointments, the Board would increase from 9 to 13 directors: the existing roster of nine ^[2] plus the four directors appointed effective November 3, 2026 ^[1].

Applying the usual one-third Board-quorum rule:

• Before: 9 directors → quorum of 3.
• After: 13 directors → one-third is 4.33, which rounds up to a quorum of 5.

This is a numerical change to the full Board’s quorum, not a change to the CID’s composition. At least one independent director would still need to be present for the Board quorum under the applicable governance framework.

The four appointees would, in principle, have voting rights in ordinary full-Board matters. However, that does not give them votes on the CID’s open-offer recommendation. If the full Board separately considers a resolution directly concerning the Burman offer, the participation of interested directors would depend on the applicable conflict-of-interest and recusal requirements. No post-appointment full-Board resolution or recusal decision on the open offer is reported in the cited sources.

Bottom line: the appointments strengthen the Burman family’s representation on the full Board and potentially raise the full-Board quorum from three to five, assuming the 9-to-13 composition. They do not alter the statutory CID voting structure: the open-offer recommendation remains an independent-director process, and the four new non-independent directors should not be members of or vote within that CID.

The current RBI approval carries a five-year ceiling, but the filing does not disclose any new conditional directive on “fit and proper” status. The four appointments became effective on November 3, 2026, as Non-Executive, Non-Independent Directors, for a term not exceeding five years from the appointment date. ^[1]

Fit-and-proper conditions

• Religare’s disclosure states that the four appointees are not debarred from holding directorships by SEBI or any other authority, and that the prescribed SEBI LODR disclosures were submitted. ^[1]
• That declaration is an eligibility disclosure; it is not the same as an RBI directive imposing additional fit-and-proper undertakings or restrictions.
• There was a separate earlier RBI action on December 9, 2024, in which RBI reportedly gave only conditional approval to the proposed new management on fit-and-proper grounds and required the acquirers to submit a consolidation plan. ^[4] The November 2026 appointment filing does not say that this earlier condition was repeated, modified, or formally discharged. Therefore, it should not be assumed that the current approval was unconditional on all historical matters.

Remaining vacancies or compliance gaps

• No further board vacancy is specifically identified in the November 3 filing. The four appointments are described as appointments of Additional Directors, not as replacements for named vacant seats. ^[1]
• The available disclosure does not provide a complete post-appointment board and committee matrix. Accordingly, it cannot confirm whether any committee reconstitution, independent-director replacement, or other board-composition action remains pending.
• The appointments themselves do not add independent directors: all four are Non-Executive and Non-Independent. ^[1] They therefore would not, by themselves, cure any potential independent-director or committee-composition shortfall; however, no such shortfall is identified in the cited filings.
• The Company Secretary and Compliance Officer position was reported as having been filled by Ms Dipti Jayesh Khandelwal effective October 31, 2026. ^[5] No additional compliance-officer vacancy is indicated after the four appointments.

Assessment: the visible approval condition is the maximum five-year tenure. A current fit-and-proper restriction is not disclosed, while the earlier 2024 conditional approval remains a historical matter whose final status is not explained in the November 2026 appointment announcement. No additional vacancy or regulatory gap is expressly reported, but a full current board-and-committee composition filing would be needed to close that verification gap.